The new guidelines, published in the Journal of the American Academy of Dermatology (JAAD), will guide dermatologists in deciding the best possible prevention and treatment options for pediatric ...

ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks Caregivers reported rapid improvement in itch in as ...

Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to 2 years old, in a phase 2 study.

Please provide your email address to receive an email when new articles are posted on . AD onset in infants was significantly delayed with high vs. low dietary diversity during pregnancy. There was a ...

WESTLAKE VILLAGE, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT) (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...

Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitis Atopic dermatitis impacts 9.6 million children ...

The American Academy of Dermatology issued its first-ever guidance for the medical management of pediatric eczema, a skin ...

A randomized clinical trial has found that applying daily full-body emollient on infants beginning before age 9 weeks reduced the risk of atopic dermatitis (AD) by the second birthday. Simpson and ...

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA ...

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a ...